rs622342 in SLC22A1, CYP2C9*2 and CYP2C9*3 and Glycemic Response in Individuals with Type 2 Diabetes Mellitus Receiving Metformin/Sulfonylurea Combination Therapy: 6-Month Follow-Up Study

Background and Objective: Since the treatment outcome with oral anti-diabetics differs between individuals, the objective of this study is to evaluate the significance of rs622342 in SLC22A1, CYP2C9*2 (rs1799853) and CYP2C9*3 (rs1057910) with regard to the efficacy of metformin/sulfonylurea combinat...

Descripción completa

Detalles Bibliográficos
Autores principales: Naja, Khaled, Salami, Ali, El Shamieh, Said, Fakhoury, Rajaa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354490/
https://www.ncbi.nlm.nih.gov/pubmed/32575674
http://dx.doi.org/10.3390/jpm10020053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354490/
https://www.ncbi.nlm.nih.gov/pubmed/32575674
http://dx.doi.org/10.3390/jpm10020053

Ejemplares similares